Key result
Myocardial bridging in athletes lacks standardized screening and management, requiring individualized shared decision-making.
Why the study?
Myocardial bridging can cause dynamic coronary compression, ischemia, arrhythmia, and sudden cardiac death during exercise, yet substantial detection gaps persist on routine screening tests.
This review highlights the lack of robust evidence for managing myocardial bridging in athletes and proposes a provisional framework for risk stratification and return-to-play decisions.
Paucity of data mandates expert consensus for athlete management; leaves open prospective validation of screening and risk stratification.
Myocardial bridging (MB) is a congenital coronary anomaly in which a segment of an epicardial coronary artery courses intramurally beneath the myocardium for part of its length, resulting in dynamic compression during systole. Once considered a largely benign incidental finding, accumulating evidence has demonstrated MB to be a clinically significant substrate for myocardial ischemia, arrhythmia, and sudden cardiac death (SCD), particularly under conditions of elevated adrenergic drive such as vigorous physical exercise. The prevalence of MB is highly dependent on the diagnostic modality used, ranging from approximately 0.5–2.5% on coronary angiography to 15–85% on post-mortem and advanced intravascular imaging studies, reflecting a substantial detection gap- in particular on routine cardiac screening tests. This review critically examines the current evidence base regarding MB in the context of competitive and recreational sport. We address: (1) the pathophysiology of exercise-induced hemodynamic compromise in MB; (2) the limitations of existing screening modalities—including electrocardiography, echocardiography, exercise stress testing, and advanced coronary imaging in identifying athletes at risk; (3) the clinical management of symptomatic MB, encompassing pharmacological therapy, coronary revascularization strategies, and catheter-based interventions; and (4) physical activity guidance for athletes with known or suspected MB.
No takes yet. Share an insight, caveat, or question.
Spaan et al. (2026) conducted a review in Myocardial bridging. Myocardial bridging was evaluated. Myocardial bridging in athletes lacks validated screening methods and evidence-based management guidelines, relying currently on expert consensus and shared decision-making due to a paucity of data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: